{"filing":{"accession_number":"0001213900-26-096443","cik":"0001614744","ticker":"PPBT","company_name":"PURPLE BIOTECH LTD.","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"ea0304192-6k_purple.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1614744/000121390026096443/ea0304192-6k_purple.htm"},"events":[{"id":31156,"run_id":28577,"accession_number":"0001213900-26-096443","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Purple Biotech announced a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use for its CAPTN-3 platform. This is a material intellectual property milestone that strengthens the company's patent estate and competitive position in its core immunotherapy platform. While not a discrete event type like M\u0026A or earnings, the patent allowance is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's IP protection and platform defensibility.","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":33965,"accession_number":"0001213900-26-096443","item_number":"EX-99.1","item_title":"ea030419201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Purple Biotech announced a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use for its CAPTN-3 platform. This is a material intellectual property milestone that strengthens the company's patent estate and competitive position in its core immunotherapy platform. While not a discrete event type like M\u0026A or earnings, the patent allowance is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's IP protection and platform defensibility.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:34:40.011895+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33965,"accession_number":"0001213900-26-096443","item_number":"EX-99.1","item_title":"ea030419201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Purple Biotech announced a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use for its CAPTN-3 platform. This is a material intellectual property milestone that strengthens the company's patent estate and competitive position in its core immunotherapy platform. While not a discrete event type like M\u0026A or earnings, the patent allowance is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's IP protection and platform defensibility.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:34:40.011895+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-09-02"}]}